Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 11/20 | 0.61 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.39 |
| ▸ | NNMT | P40261 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25884637 | 0.82 | HCAR3 (0.65) | HCAR3HCAR2GRM5NNMT | |
| SCHEMBL16799770 | 0.75 | HCAR3 (0.73) | HCAR3HCAR2NNMT | |
| SCHEMBL20812007 | 0.75 | HDAC1 (0.50) | HCAR3GRM5NAMPTKDM4EALDH1A1 | |
| SCHEMBL3247777 | 0.74 | NAPRT (0.53) | GRM5ALDH1A1POLB | |
| SCHEMBL12844433 | 0.74 | HCAR3 (0.42) | HCAR3GRM5NAMPTHRH3 | |
| SCHEMBL28630671 | 0.73 | P4HTM (0.58) | HCAR3KDM4EALDH1A1 | |
| SCHEMBL29024751 | 0.73 | HCAR3 (0.41) | HCAR3GRM5NAMPTHRH3 | |
| Isopropylamine SCHEMBL16799393 | 0.73 | HCAR3 (0.90) | HCAR3HCAR2 | |
| Isopropylamine SCHEMBL16799391 | 0.73 | HCAR3 (0.90) | HCAR3HCAR2 | |
| SCHEMBL23991487 | 0.72 | ALDH1A1 (0.42) | GRM5NAMPTKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | HCAR3 4223/4885HCAR2 4169/4885GRM5 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.